Tolerance in Antidepressant Treatment
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Despite compelling evidence of rapid relapse into depression within 1–3 months after discontinuing long-term antidepressant treatment, and a strong relationship of this risk to prior illness history, the place for maintenance antidepressant treatment in recurrent major depression and other disorders remains uncertain [1, 2]. Most long-term therapeutic studies in major depression involve tricyclic antidepressants; they average 17 months in duration [1, 2]; only one small trial of imipramine reached 5 years [3]. The therapeutic model involved derives from evidence of protective effects of long-term lithium treatment in unipolar as well as bipolar major affective disorders [4, 5]. Evidence of long-term effectiveness and safety for antidepressant treatment in bipolar disorders is lacking [2, 6]. There is also growing evidence that a loss of benefit can emerge with long-term antidepressant treatment or on retreatment after discontinuation [7, 8, 9, 10], perhaps even more commonly among bipolar than unipolar depressed patients [11].In this issue, Schmidt et al. [12]and Fava et al. [13]provide relevant observations from their long-term collaborative study of outpatients with moderately severe, recurrent unipolar depression who relapsed during long-term treatment with (±)-fluoxetine. They extend previous observations that increasing fluoxetine doses from 20 to 40 mg/day can rescue some late failures [14], as did increasing the dose of enteric-coated fluoxetine tablets from 90 to 180 mg/week [12](table 1). Underlying mechanisms and implications of this phenomenon remain unclear, but invite comment.After responding to an open trial of fluoxetine at 20 mg/day, 31.4% (119/379) of depressives relapsed within an average of 107 days of blinded fluoxetine maintenance treatment, in which daily dosing was somewhat more effective than weekly (25.9 vs. 36.8% relapse rate; χ2 = 5.24, p = 0.022) [15]. Among 56 subjects relapsing at 20 mg/day, 57.1% responded to a blindly determined doubled dose of fluoxetine for another 6–24 weeks, as did 71.9% of 64 patients who relapsed on 90 mg/week of enteric-coated drug. Therefore, 35.0% (42/120) of patients relapsing during long-term fluoxetine treatment were not rescued by doubling the dose. These treatment-resistant subjects represent 11.0% (0.314 × 0.350) of all subjects starting long-term fluoxetine treatment.As expected, more patients relapsed during blinded maintenance with a placebo (61/122 = 50.0%) than with fluoxetine [119/379 = 31.4%; χ2 (1 d.f.) = 13.9, p = 0.0002], and with a shorter average latency (2.87 vs. 3.57 months) [12]. The larger relapse risk with placebo suggests that a loss of placebo response did not account for relapses during fluoxetine maintenance. Of those maintained on placebo after blinded withdrawal from 13 weeks of open treatment with fluoxetine, 62.3% (33/53) regained and maintained response to 20 mg/day on retreatment [13].Response during secondary trials of fluoxetine was unexpectedly greater than in primary trials [431/932 = 46.2% vs. 42/120 = 35.0% of subjects; χ2 (1 d.f.) = 5.43, p = 0.020]. This finding does not indicate any loss of response to retreatment. However, sampling may be biased by including all eligible subjects initially, but retreating only initially fluoxetine-responsive patients. Relative risk of unresponsiveness to retreatment with other antidepressants remains inadequately studied [7, 8, 9, 10, 11], but preliminary findings suggest variance among specific agents [11]. Similarly, responses to retreatment after failing lithium among bipolar disorder patients have been inconsistent [16, 17].It is reassuring that increasing the dose of fluoxetine led to sustained secondary responses in a majority (78/120 = 65.0%) of relapsed depressive patients, though only with limited follow-up (6–24 weeks) [12]. More concerning, however, is that 35% of patients relapsing during maintenance fluoxetine treatment did not respond to an increased dose, and that 11% of those started on long-term fluoxetine treatment became treatment resistant within only about 3.6 months of maintenance treatment [12, 15].Loss of previous antidepressant benefit over time, with incomplete return of response even after doubling the drug dose, are consistent with pharmacological tolerance. Underlying mechanisms are unknown, but induced metabolic clearance of antidepressants is readily tested with assays of blood drug concentrations over time. It also remains to be proved, as we suspect [11], that antidepressants vary in risk of therapeutic tolerance, and whether longer antidepressant treatment, or higher maintenance doses might further increase the risk of tolerance.That dosing may be significant is suggested by the finding [12]that response to increased dosing was nearly significantly greater among those maintained with the lesser dose of 90 mg/week (equivalent to 12.9 mg/day) vs. 20 mg/day of fluoxetine [respective secondary failure rates: 18/64 = 28.1% vs. 24/56 = 42.9%; χ2 (
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, whenever assessed, maintenance antidepressant drug trials for MDD rarely exceeds 52-week duration [15]”
Citations
Cites
Three-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Diagnosing Bipolar Disorder and the Effect of Antidepressants: A Naturalistic Study
Ghaemi, S. N., Boiman, E. E., & Goodwin, F. K. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1013 · Cited by 501
Self-citationClinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246
Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications
Baldessarini, R. J., Tondo, L., & Viguera, A. C. (1999) · Bipolar Disorders · doi:10.1034/j.1399-5618.1999.10106.x · Cited by 153
Effectiveness and Safety of Long-Term Antidepressant Treatment in Bipolar Disorder
Ghaemi, S. N., Lenox, M. S., & Baldessarini, R. J. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n07a12 · Cited by 138
Is Lithium Still Worth Using? An Update of Selected Recent Research
Baldessarini, R. J., Tondo, L., Hennen, J., & Viguera, A. C. (2002) · Harvard Review of Psychiatry · doi:10.1080/10673220216208 · Cited by 86
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.12.1810 · Cited by 77
Schmidt, M. E., Fava, M., Robinson, J. M., & Judge, R. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1107 · Cited by 68
Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.
D, M. F. M., Rappe, S., Pava, J. A., Nierenberg, A. A., Alpert, J. E., & Rosenbaum, J. F. (1995) · PubMed · Cited by 63
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.548 · Cited by 61
Cited by
Six-Year Outcome of Cognitive Behavior Therapy for Prevention of Recurrent Depression
Fava, G. A., Ruini, C., Rafanelli, C., Finos, L., Conti, S., & Grandi, S. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1872 · Cited by 392
“First, long-term treatment with antidepressant drugs is not exempt from considerable problems (18), in particular, the loss of clinical effect (19).”
BackgroundFava, G. A., & Ruini, C. (2003) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/s0005-7916(03)00019-3 · Cited by 386
Increasing Psychological Well‐Being and Resilience by Psychotherapeutic Methods
Fava, G. A., & Tomba, E. (2009) · Journal of Personality · doi:10.1111/j.1467-6494.2009.00604.x · Cited by 362
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
“Several clinical observations point to the existence of tolerance phenomena during antidepressant treatment.(24,55)”
BackgroundChouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
“In a subsequent analysis (Baldessarini et al., 2002), including one more study (Schmidt et al., 2002), risk of post-discontinuation relapse was nearly significantly greater after long treatment following recovery from an index episode of major depression (rho=0.37; p=0.052).”
InfluentialAndrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107
“While this relationship was not statistically significant, it became marginally significant in a re-analysis that included an additional study (Baldessarini et al., 2002).”
Rational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Fornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., Solmi, M., Veronese, N., Stubbs, B., Vieta, E., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.025 · Cited by 80
Clinical Applications of Well‐Being Therapy
Ruini, C., & Fava, G. A. (2004) · Wiley eBooks · doi:10.1002/9780470939338.ch23 · Cited by 88
Treatment of Recurrent Depression: A Sequential Psychotherapeutic and Psychopharmacological Approach
Fava, G. A., Ruini, C., & Sonino, N. (2003) · CNS Drugs · doi:10.2165/00023210-200317150-00005 · Cited by 70
Why is it so difficult to stop psychiatric drug treatment?
Moncrieff, J. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.03.009 · Cited by 59
“That is, relapse risk was increased by the same amount on withdrawal to placebo after less than 3 weeks or 4 years of prior maintenance treatment [30].”
BackgroundLin, Z., Canales, J. J., Björgvinsson, Þ., Thomsen, M., Qu, H., Liu, Q., Torres, G. E., & Caine, S. B. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385506-0.00001-6 · Cited by 65
“Tolerance can emerge with long-term antidepressant treatment or on retreatment after discontinuation (348).”
BackgroundMajor Depressive Disorder with Anger: A Bipolar Spectrum Disorder?
Benazzi, F. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000073026 · Cited by 52
“DSM-IV-TR subtyping of MDD can only partly predict treatment response. As the probability of responding to a first antidepressant is around 50p, in MDD, but nearly 30p of MDD patients may lose response [”
BackgroundTreatment of recurrent depression
Fava, G. A., Park, S. K., & Sonino, N. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.11.1735 · Cited by 36
Antidepressant Dose Reduction and the Risk of Relapse in Major Depressive Disorder
Papakostas, G. I., Perlis, R. H., Seifert, C., & Fava, M. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000104702 · Cited by 38
Inter‐episode mood lability in mood disorders: residual symptom or natural course of illness?
Benazzi, F. (2004) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2004.01289.x · Cited by 34
Patten, S. B. (2004) · Population Health Metrics · doi:10.1186/1478-7954-2-9 · Cited by 28
“, which found that subjects taking antidepressant medications for longer periods were more likely to relapse upon discontinuation [13].”
BackgroundConflict of Interest in Psychopharmacology: Can Dr. Jekyll Still Control Mr. Hyde?
Fava, G. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000074433 · Cited by 24
Increased alcohol consumption in rats after subchronic antidepressant treatment
Alén, F., Orío, L., Gorriti, M. Á., de Heras, R. G., Ramírez-López, M. T., Pozo, M. A., & de Fonseca, F. R. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000217 · Cited by 24
“, 2006), the development of tolerance (Rapport and Calabrese, 1993; Baldessarini et al., 2002), difficulties quitting this medication (Menecier et al.”
BackgroundFaravelli, C., Cosci, F., Ciampelli, M., Scarpato, M. A., Spiti, R., & Ricca, V. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000068689 · Cited by 22
“Moreover, some psychiatrists still prescribe TCAs emphasizing their greater effectiveness, at least in severe depression and recent papers emphasize the weak efficacy of SSRIs [”
BackgroundManagement of Recurrent Depression in Primary Care
Fava, G. A., Ruini, C., & Sonino, N. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000067189 · Cited by 20
“Even though lifelong pharmacotherapy is chosen (table 2 ), there is the common and vexing problem of relapse during pharmacotherapy [”
BackgroundTolerance to antidepressant treatment may be overcome by ketoconazole. Report of two cases
Sonino, N., & Fava, G. A. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00089-4 · Cited by 19
Positive Psychotherapy and Social Change
Fave, A. D., & Fava, G. A. (2010) · Springer eBooks · doi:10.1007/978-90-481-9938-9_15 · Cited by 17
Viejas y nuevas cuestiones en las viejas y nuevas terapias psicológicas
Barberá, V. P. (2007) · Revista de Psicopatología y Psicología Clínica · doi:10.5944/rppc.vol.12.num.2.2007.4035 · Cited by 11
Unipolar depression with bipolar family history: Links with the bipolar spectrum
Benazzi, F. (2003) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2003.01154.x · Cited by 12
What Is the Optimal Treatment of Mood and Anxiety Disorders?
Fava, G. A., & Ruini, C. (2005) · Clinical Psychology Science and Practice · doi:10.1093/clipsy.bpi011 · Cited by 13
Reconnaître les symptômes psychiatriques iatrogènes liés aux antipsychotiques
Demily, C., Chouinard, V., & Chouinard, G. (2010) · L Encéphale · doi:10.1016/j.encep.2010.01.003 · Cited by 5
The inhibition of phosphodiesterase type 5 as a novel target for antidepressant action
Liebenberg, N. (2009) · Cited by 5
An Editor’s Journey Ends, but the Journal’s Mission Continues
Fava, G. A. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524654 · Cited by 5
In reply: How long should drug treatment of depression last?
Ellis, P. M. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05341.x · Cited by 2
Depression: Current Conceptual Trends
Nahas, Z. H. (2016) · Springer eBooks · doi:10.1007/978-1-59745-495-7_1 · Cited by 1
Murphy, M. P. (2006) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
Demily, C., & Chouinard, G. (2010)
Les effets indésirables des antidépresseurs
Healy, D. T. (2009) · Elsevier eBooks · doi:10.1016/b978-2-8101-0116-0.50005-6
La dépendance physique de type 3
Healy, D. (2009) · Elsevier eBooks · doi:10.1016/b978-2-8101-0116-0.50023-8
How long should drug treatment of depression last?
Fava, G. A., Ruini, C., & Tossani, E. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05340.x
Joel Paris, M. D. (2010) · Wiley eBooks · doi:10.1002/9780470666630.refs
Introduction to Deprescribing Psychiatric Medications
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg001
Digvijaya, Mittal, S., Mittal, P., Singh, R., Gupta, S., Singh, T., Khan, R., Alzobaidi, N., & Alhalmi, A. (2024) · Scientifica · doi:10.1155/2024/9978076
Antidepressant Medication and Psychotherapy: Why It Matters
Chiesa, M. (2024) · British Journal of Psychotherapy · doi:10.1111/bjp.12938
Comprendre la physiopathologie des syndromes de sevrage
Fava, G. A., & Peretti, C.-S. (2024) · Elsevier eBooks · doi:10.1016/b978-2-294-77932-9.00004-2
Metadata
- Authors
- Baldessarini, R. J., Ghaemi, S. N., & Viguera, A. C.
- Affiliations
- Harvard University (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 71
- Issue
- 4
- Pages
- 177-179
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W1968373061
- Cited by
- 42
- References
- 16
- Citations by year
- 2024: 4 · 2022: 1 · 2018: 1 · 2016: 1 · 2014: 1 · 2013: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- antidepressant treatment, recurrent major depressive disorder, fluoxetine, dose escalation, tricyclic antidepressants, bipolar depression, lithium
- MeSH terms
- Major Depressive Disorder, Drug Administration Schedule, Drug Tolerance, Fluoxetine, Humans, Recurrence, Treatment Refusal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.